Creative Animodel is an experienced provider of toxicology assays. With professional experts and state-of-the-art technologies, we can provide high-quality and reliable drug cardiotoxicity assays to accelerate your drug discovery and development.
An Overview of Cardiotoxicity
The National Cancer Institute (NCI) has defined the cardiotoxicity as “toxicity that affects the heart”. With the advent of pharmaceuticals for conditions such as cancer, cardiotoxicity characterized by abnormality of cardiac electrical activity and contractile dysfunction has often been observed. Cardiotoxicity of drugs includes a direct damage to the heart and indirect effects because of the enhancement of haemodynamic flow alterations or thrombotic events. Drug-induced cardiotoxicity can be divided into 3 parts at the molecular level, including direct damage to mitochondria, disruption of kinase signaling pathways, and inhibition of cardiac ion channels. Adverse cardiac effects are the main reason for drug discontinuation and failure of clinical trials. It is reported that cardiotoxicity is responsible for 40% of drugs withdrawn between 1994 and 2006. What’s more, about 10% of drugs have been recalled from the market owing to cardiovascular concerns in the last four decades. Therefore, information obtained from cardiotoxicity is essential for the drug development. The early and efficient assessment of cardiac safety plays a significant role to confidently accelerate novel drug development.
Figure 1. Examples of major mechanisms causing cardiotoxicity of anticancer treatments (black text), clinically used therapeutic agents (green text), and potential protective agents (blue cursive text). (Albini A., 2010)
Available Cardiotoxicity Services
Preclinical cardiotoxicity screening should be carried out to detect unsafe compounds sufficiently early in the drug discovery process to help make right decisions about candidate drug selection, reduce late-stage attrition, as well as save time and costs. Creative Animodel provides reliable and professional assays for cardiotoxicity.
• Microelectrode Array Cardiotoxicity Assays
• Cardiovascular Toxicology
• hERG Inhibition
• Cardiac Channels
• Action Potential Duration
• Cardiomyocyte Toxicity
• QT Prolongation Assay
• Arrhythmogenic Liability Screening
• Comprehensive in Vitro Proarrhythmia Assay (CiPA)
• Perfused Heart
• 3D Cardiotoxicity Assay
• Professional assay platforms to offer reliable data
• Human pluripotent stem cell-derived cardiomyocytes available
• Diverse approaches to detect and characterize cardiac safely risks
• Assays conducted according to regulatory guidances
With years of experience, Creative Animodel offers a wide range of toxicology and safety pharmacology assays for the early stage of drug discovery and development. Our cardiotoxicity services provide clients high-quality data to detect cardiac risk and support drug discovery in a cost-effective and time-saving manner. If you have any questions or specific needs, please feel free to contact us.
Albini A. et al.; Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. Journal of the National Cancer Institute. 2010, 102(1): 14-25.